Anti-CD40 Monoclonal Antibody Synergizes with CTLA4-Ig in Promoting Long-Term Graft Survival in Murine Models of Transplantation
Christopher R. Gilson(Emory University), Christian P. Larsen(Emory University Hospital), Diane Hollenbaugh(Neoleukin Therapeutics (United States)), Shivaprakash Gangappa(Emory University), Mandy L. Ford(Emory Healthcare), Zvonimir L. Milas(Emory University), Thomas C. Pearson(Emory Healthcare)
Cited by 77
Related Papers
Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways
|Nature|1996|1.5k
The CD40 ligand, gp39, is defective in activated T cells from patients with X-linked hyper-IgM syndrome
|Cell|1993|824
4-1BB Costimulatory Signals Preferentially Induce CD8+ T Cell Proliferation and Lead to the Amplification In Vivo of Cytotoxic T Cell Responses
|The Journal of Experimental Medicine|1997|802
Rational Development of LEA29Y (belatacept), a High-Affinity Variant of CTLA4-Ig with Potent Immunosuppressive Properties
|American Journal of Transplantation|2005|714
Heterologous immunity provides a potent barrier to transplantation tolerance
|Journal of Clinical Investigation|2003|571